Interview with Jean-Pierre Delwart, Chief Executive Officer, Eurogentec Belgium
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Address: Dorp 14a
3272 Testelt
Belgium
Tel: +32 1 333 8071
Web: http://www.pharm-olam.com/
Established and privately held since 1994, Pharm-Olam is a leading mid-size CRO with multi-national presense in over 40 countries.
Pharm-Olam delivers cost-effective, quick-to-market clinical services in emerging and traditional markets of research along with experience in a broad range of therapeutic areas and phases of development.
Pharm-Olam data services integrate randomization into EDC systems, eliminating IVRS costs, with added benefit of full inventory control over supplies.
Our multi-national pharmacovigilance team provides 24/7 coverage from our safety units in USA and Europe to electronically collect, assess and report (S)AEs, SUSARs, and ADRs for secure reporting to sponsors, regulatory agencies, sites and ethics committees.
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Can you illustrate to our readers the company’s main milestones and key achievements since you took the reins four years ago? In the last years we have experienced a period…
Let us begin by getting an overview of APB’s functions & objectives and your role within the association as General Manager? The Belgian Association of Pharmacists is a federation of…
Mr Bravo, in relation to your previous career in big pharma companies, you have recently made a shift into much smaller entities including Cellerix and TiGenix. What motivated you to…
Looking into your background, we see that you have developed your career in the local industry’s top 3 players: Pfizer, AstraZeneca and Novartis until assuming your position as General Manager…
Oystershell was founded in 1979, however in 2002 the company was taken over by you and your team in a MBO. Can you tell our readers more about what motivated…
Can you tell our readers about B&C Groups main mission and also highlight some of its most notable achievements and milestones since its founding in 1999? Earlier in my career,…
Looking at your background, we see that you have been with IMS for over 12 years. What defines your loyalty to the company? What appeals most to you about IMS?…
Can you begin by giving us a brief overview of Amgen in Belgium and tell our readers more about the company’s history here? Compared to other, well-established multinationals Amgen is…
Mr. De Cuyper, can you start with a brief introduction to the federal agency for medicines and health products (famhp) and its role within the Belgium’s complex regulatory environment? We…
Looking into your background, we see that you’ve spent 8 years at pharma.be, where you were advocating the traditional drug producers. What encouraged you to head FeBelGen since 2006, representing…
In your 8 years of experience within the group, how would you classify the competitive advantages derived for the company’s unique familial ownership structure? Due to its history and strong…
See our Cookie Privacy Policy Here